Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Pfizer (PFE) investors are bound to be disappointed with the stock’s price action. With a year-to-date loss of 16.7% as of ...

The failure of Pfizer Inc.’s obesity pill, its highest profile experimental drug, raises the odds that the drugmaker will ...

Pfizer just pulled the plug on its daily weight-loss pill, danuglipron, after a clinical trial flagged a potential ...

Pfizer Inc. has said it will discontinue development of its closely watched obesity pill, danuglipron, dealing a severe blow ...

With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog ...

When some of America’s most-influential CEOs were asked recently how much the stock market would need to fall before they ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

China is prepared for “possible unexpected shocks,” Premier Li Qiang told a gathering of global executives in Beijing, where he urged them to “resist protectionism” and defend globalization.